Non-Viral CAR NK Platforms for Broad Therapeutic Applications in Cancer & Beyond

• Advancing non-viral CAR-NK platforms: Development of mRNA and circRNA-based CAR-NK systems enabling rapid, scalable, and safer manufacturing compared to viral approaches
• Overcoming key barriers in solid tumors: Strategies to address antigen shedding (e.g., MSLN), CAR downregulation, and TME-mediated suppression (including TGF-Beta resistance and metabolic reprogramming)
• Expanding therapeutic scope beyond oncology: Application of engineered NK cells in non-malignant diseases, highlighting next-generation targets and translational opportunities

Speakers:

Mihue Jang

Principal Research Scientist

KIST(Korea Institute of Science and Technology)